[Combined chemotherapy with cisplatin and aclarubicin hydrochloride for metastatic brain tumors].
Thirteen patients with metastatic brain tumors were treated by combined chemotherapy with cisplatin and aclarubicin hydrochloride. Initial response to this therapy was evaluated by the changes of tumor size on CT scan and clinical state during and after the treatment. The side effects and the causes of death were also studied. Nine cases demonstrated complete remission and 3 cases revealed partial response on CT scan. In short, over all response rate was 92%. Clinical state evaluated by Karnofsky scale was improved in 9 out of 13 cases. As the side effects, there were mild myelosuppression, nausea and vomiting, which didn't persist for a long time. The cause of death was mainly due to recurrence of primary lesion. The tissue concentration of aclarubicin hydrochloride was measured in 6 patients, of which mean value was 0.558 microgram/g at 15 min. The concentration was thought high enough to kill tumor cells.
Tanaka
T
T
Department of Neurosurgery, School of Medicine, Nagoya University, Japan.
Kobayashi
T
T
Kida
Y
Y
D015250:Aclarubicin; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D015250:Aclarubicin; D002945:Cisplatin